Coloma Jason V sold $117K of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 4,504 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.00 ($0.12M total) on 2026-05-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider selling disclosures can influence short-term sentiment, but 10b5-1 plans are designed to mitigate timing-based trading signals; no new company-specific catalyst is included here.
Market read
Traders may monitor MAZE for follow-on insider activity, but this specific filing alone is unlikely to reset valuation expectations.
What to watch
The article provides only the sale details; without context on total insider activity, option exercises, or concurrent buys, directional inference is weak.
Background
The article reports an SEC Form 4 insider transaction for Maze Therapeutics, Inc., filed by its CEO and executed under a Rule 10b5-1 plan.
Ticker impact
SEC Form 4 shows MAZE CEO Coloma Jason V sold 4,504 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.
The filing is a routine 10b5-1 plan sale with no accompanying operational, clinical, or deal catalyst mentioned in the article.
Market effects
Minimal—no sector-wide regulatory/clinical/deal catalyst is described.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the insider transaction disclosure (CEO sale under a pre-arranged 10b5-1 plan).
- insiderColoma Jason V
CEO/director who sold 4,504 shares at ~$26.0001/share per the Form 4.